Moderna Inc will not be ready to apply for emergency authorization for its potential COVID-19 vaccine before the U.S. presidential election in November, the Financial Times reported on Wednesday, citing the company's chief executive officer.
FILE PHOTO: A sign marks the headquarters of Moderna Therapeutics, which is developing a vaccine against the coronavirus disease , in Cambridge, Massachusetts, U.S., May 18, 2020. REUTERS/Brian Snyder
Stéphane Bancel told FT that he did not expect to have full approval to distribute the drug to all sections of the U.S. population until next spring. Moderna will not be ready to seek emergency use authorization from the Food and Drug Administration before Nov. 25 at the earliest, the report said, citing Bancel.
The race to come up with a vaccine has become a divisive issue for the U.S. presidential election and was of significant importance in the presidential debate on Tuesday between U.S. President Donald Trump and contender Joe Biden.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Lonza confident of 2020 target for Moderna COVID-19 vaccine supplyLonza is confident that U.S. and Swiss plants it is building to help make Moderna's COVID-19 vaccine candidate will be ready for commercial production this year, executives at the Swiss company said on Tuesday.
Weiterlesen »
Moderna COVID-19 vaccine appears safe, shows signs of working in older adults - studyResults from an early safety study of Moderna Inc's coronavirus vaccine candidate in older adults showed that it produced virus-neutralizing antibodies at levels similar to those seen in younger adults, with side effects roughly on par with high-dose flu shots,...
Weiterlesen »
Moderna COVID-19 vaccine appears safe, shows signs of working in older adults - studyResults from an early safety study of Moderna Inc's coronavirus vaccine candidate in older adults showed that it produced virus-neutralizing antibodies at levels similar to those seen in younger adults, with side effects roughly on par with high-dose flu shots, researchers...
Weiterlesen »
Lonza confident of 2020 target for Moderna COVID-19 vaccine supplyLonza is confident that U.S. and Swiss plants it is building to help make Moderna's COVID-19 vaccine candidate will be ready for commercial production this year, executives at the Swiss company said on Tuesday.
Weiterlesen »
China reports 19 new COVID-19 cases vs. 12 a day earlierMainland China reported 19 new COVID-19 cases on Sept. 29, up from 12 a day earlier, the country's national health authority said on Wednesday.
Weiterlesen »
'Healthy' college student, 19, with 'so much life ahead' dies from Covid-19Chad Dorrill, a second-year student at Appalachian State University, had recovered from flu-like symptoms before developing complications.
Weiterlesen »